PharmChem Statistics
Total Valuation
PharmChem has a market cap or net worth of 13.94 million.
| Market Cap | 13.94M |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | Oct 10, 2024 |
Share Statistics
PharmChem has 4.65 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 4.65M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.54 |
| PB Ratio | 1.83 |
| P/TBV Ratio | 1.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.69, with a Debt / Equity ratio of 0.37.
| Current Ratio | 0.69 |
| Quick Ratio | 0.09 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.65 |
Financial Efficiency
Return on equity (ROE) is -23.67% and return on invested capital (ROIC) is -7.34%.
| Return on Equity (ROE) | -23.67% |
| Return on Assets (ROA) | -5.37% |
| Return on Invested Capital (ROIC) | -7.34% |
| Return on Capital Employed (ROCE) | -19.98% |
| Revenue Per Employee | 151,329 |
| Profits Per Employee | -12,012 |
| Employee Count | 170 |
| Asset Turnover | 1.44 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.70% in the last 52 weeks. The beta is 0.69, so PharmChem's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | +10.70% |
| 50-Day Moving Average | 3.21 |
| 200-Day Moving Average | 2.91 |
| Relative Strength Index (RSI) | 43.24 |
| Average Volume (20 Days) | 9,465 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, PharmChem had revenue of 25.73 million and -2.04 million in losses. Loss per share was -0.35.
| Revenue | 25.73M |
| Gross Profit | 5.74M |
| Operating Income | -1.53M |
| Pretax Income | -2.04M |
| Net Income | -2.04M |
| EBITDA | n/a |
| EBIT | -1.53M |
| Loss Per Share | -0.35 |
Balance Sheet
The company has 626,000 in cash and 2.82 million in debt, giving a net cash position of -2.20 million or -0.47 per share.
| Cash & Cash Equivalents | 626,000 |
| Total Debt | 2.82M |
| Net Cash | -2.20M |
| Net Cash Per Share | -0.47 |
| Equity (Book Value) | 7.63M |
| Book Value Per Share | 1.30 |
| Working Capital | -2.23M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 22.32%, with operating and profit margins of -5.96% and -7.94%.
| Gross Margin | 22.32% |
| Operating Margin | -5.96% |
| Pretax Margin | -7.94% |
| Profit Margin | -7.94% |
| EBITDA Margin | n/a |
| EBIT Margin | -5.96% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.25, which amounts to a dividend yield of 8.42%.
| Dividend Per Share | 0.25 |
| Dividend Yield | 8.42% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 3 |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 8.42% |
| Earnings Yield | -14.65% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |